transmembrane p24 trafficking protein 10 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored TMED10P2 profile across patient tissues and cancer cell-line models. TMED10P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMED10P2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TMED10P2 RNA expression shows 14,406 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where TMED10P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMED10P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMED10P2 survival associations across molecular data types. TMED10P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMED10P2 RNA expression–survival associations across cancer types. High TMED10P2 expression shows unfavorable associations in DLBC, COAD and CESC, but favorable associations in KIRC, LGG and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMED10P2 RNA expression.
This table summarizes TMED10P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMED10P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMED10P2 shows lower tumor expression in KIRC, LUSC, THCA, LUAD and KIRP and higher tumor expression in HNSC. The KIRC box plot shows higher TMED10P2 RNA expression in normal versus tumor tissue (log2 FC = −1.518, t-test p < 0.001).
This table shows molecular features associated with TMED10P2 in patient tissues and cancer cell lines. In patient samples, TMED10P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
